C-Reactive Protein as a Marker for Inflammatory Bowel Disease

The production of CRP occurs almost exclusively in the liver by the hepatocytes as part of the acute phase response upon stimulation by IL-6, TNF-&agr;and IL-1-βoriginating at the site of inflammation. Its short half-life makes CRP a valuable marker to detect and follow up disease activity in Crohn’s disease (CD). In contrast, ulcerative colitis has only a modest to absent CRP response despite active inflammation, and the reason for this is unknown. In CD, serum levels of CRP correlate well with disease activity and with other markers of inflammation as the CDAI, serum amyloid, IL-6 and faecal calprotectin. CRP is a valuable marker for predicting the outcome of certain diseases as coronary heart disease and haematological malignancies. An increased CRP (>45 mg/L) in patients with IBD predicts with a high certainty the need for colectomy and this by reflecting severe ongoing and uncontrollable inflammation in the gut. Finally, trials with anti-TNF and anti-adhesion molecules have shown that a high CRP predicts better response to these drugs. However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate.

[1]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[2]  J. Belaiche,et al.  Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.

[3]  D. Alarcón-Segovia,et al.  A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. , 2002, American journal of human genetics.

[4]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[5]  B. Klein,et al.  C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. , 1992, Arthritis and rheumatism.

[6]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[7]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[8]  J. Harley,et al.  Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. , 1999, Arthritis and rheumatism.

[9]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[10]  E. Eicher,et al.  A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice , 1984, The Journal of experimental medicine.

[11]  B. Schumacher,et al.  Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. , 1997, Hepato-gastroenterology.

[12]  C. Mold,et al.  Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. , 2002, Journal of autoimmunity.

[13]  D. Mannino,et al.  C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. , 2003, Clinical chemistry.

[14]  J. Wright,et al.  Predictors of acute relapse of Crohn's disease , 1987, Digestive Diseases and Sciences.

[15]  A. Tall.  C-reactive protein reassessed. , 2004, The New England journal of medicine.

[16]  J. Whittaker,et al.  Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. , 2003, Human molecular genetics.

[17]  Thomas Francis,et al.  SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.

[18]  B. Shine,et al.  C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[19]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[20]  W. Sandborn.  Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease , 2003, Current gastroenterology reports.

[21]  R. Hegele,et al.  Human C-reactive protein (CRP) 1059G/C polymorphism , 2000, Journal of Human Genetics.

[22]  T. Kvien,et al.  A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. , 1995, Clinical and experimental rheumatology.

[23]  A. Zinsmeister,et al.  Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[24]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[25]  C. Mold,et al.  Serum Amyloid P Component and C-Reactive Protein Opsonize Apoptotic Cells for Phagocytosis through Fcγ Receptors , 2002 .

[26]  S. Murch,et al.  Indications for investigation of chronic gastrointestinal symptoms. , 1995, Archives of disease in childhood.

[27]  R. Modigliani,et al.  Biological markers of short term relapse in Crohn's disease (CD) , 2001 .

[28]  H. Hodgson,et al.  Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. , 1992, Gut.

[29]  R. Cantor,et al.  Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. , 1997, The Journal of clinical investigation.

[30]  M. Pepys,et al.  Differing acute phase responses in Crohn's disease and ulcerative colitis. , 1986, Gut.

[31]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[32]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[33]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[34]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[35]  I. Kushner,et al.  C-reactive protein and the acute-phase response. , 1990, Hospital practice.

[36]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[37]  A. Poullis,et al.  A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders , 2002, European journal of gastroenterology & hepatology.

[38]  H. Colten,et al.  Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. , 1983, Science.

[39]  B. Klein,et al.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.

[40]  P. Butler,et al.  Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity , 1999, Nature Medicine.

[41]  P. Mcgeer,et al.  Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease , 2000, Brain Research.

[42]  S. Fais,et al.  The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. , 1988, Journal of clinical gastroenterology.

[43]  G. Cooper,et al.  Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene , 2002, Genes and Immunity.

[44]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[45]  A. Petrie,et al.  Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis , 1982, European journal of clinical investigation.